Syncromune® Inc. to Present Initial Clinical Data from SYNC-T™ SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024Presentation will take place during the “Cancer Vaccines: Ready for Prime Time?” session onApril 7, from 3:00 - 5:00pm PT at the San Diego Convention CenterMarch...